This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Statin and antiplatelet drugs in CKD

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Statins and antiplatelet drugs

  • statin:
    • offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD
      • increase the dose if a greater than 40% reduction in non-HDL cholesterol is not achieved and eGFR is 30 ml/min/1.73 m2 or more
      • agree the use of higher doses with a renal specialist if eGFR is less than 30 ml/min/ 1.73 m2
    • offer statins to people with CKD for the secondary prevention of CVD irrespective of baseline lipid values

  • antiplatelet drugs
    • offer antiplatelet drugs to people with CKD for the secondary prevention of CVD. CKD is not a contraindication to the use of low dose aspirin but clinicians should be aware of the increased risk of minor bleeding in people with CKD given multiple antiplatelet drugs
      • consider apixaban in preference to warfarin in people with a confirmed eGFR of 30-50 ml/min/1.73 m2 and non-valvular atrial fibrillation who have 1 or more of the following risk factors:
        • prior stroke or transient ischaemic attack
        • age 75 years or older
        • hypertension
        • diabetes mellitus
        • symptomatic heart failure

  • there is insufficient evidence to recommend the routine use of drugs to lower uric acid in people with CKD who have asymptomatic hyperuricaemia

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.